NCT04562441View on ClinicalTrials.gov

NPC - AXEL Study : Axitinib-Avelumab

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

November 7, 2024

Conditions
Recurrent or Metastatic NPC
Interventions
DRUG

Axitinib

Axitinib: 5 mg bd po Day 1 to Day 28

DRUG

Avelumab

Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks

Trial Locations (1)

Unknown

Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER